477 results on '"Rawstron, Andy C."'
Search Results
2. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity
3. Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL
4. Laboratory Diagnosis of Chronic Lymphocytic Leukaemia
5. Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment
6. Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study
7. Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
8. Histopathology, Morphology and Immunophenotyping of CLL
9. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity
10. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
11. Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells
12. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
13. Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation
14. Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment
15. OA13 Comprehensive genetic and functional analyses of Fc gamma receptors explain response to rituximab therapy for autoimmune rheumatic diseases
16. P245 Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren’s Syndrome
17. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis
18. Clinical and diagnostic implications of monoclonal B-cell lymphocytosis
19. A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
20. Monoclonal B Cell Lymphocytosis—What Does It Really Mean?
21. Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?
22. Assessing minimal residual disease in chronic lymphocytic leukemia
23. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
24. Minimal residual disease assessment in chronic lymphocytic leukaemia
25. P207 A proposal for individually tailored rituximab treatment based on clinical and B-cell biomarkers for remission maintenance in ANCA associated vasculitis
26. Histopathology, Morphology and Immunophenotyping of CLL
27. Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism
28. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
29. Translocation t(14;16) in IgM multiple myeloma
30. Defining IgM multiple myeloma
31. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
32. Occult B-cell lymphoproliferative disorders
33. Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure
34. Extramedullary plasmacytoma are characterized by a ‘myeloma-like’ immunophenotype and genotype and occult bone marrow involvement
35. CD52 Expression in Waldenström's Macroglobulinemia: Implications for Alemtuzumab Therapy and Response Assessment
36. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis
37. IgM myeloma: a rare entity characterized by a CD20−CD56−CD117− immunophenotype and the t(11;14)
38. Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience
39. The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia
40. Overview of monoclonal B-cell lymphocytosis
41. Cyclooxygenase-2 (COX-2) in multiple myeloma: prognostic factor or therapeutic target?
42. Immunoglobulin Heavy Chain Sequence Analysis in Waldenströmʼs Macroglobulinemia and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance
43. MBL and MoBL
44. Diagnostic criteria for monoclonal B-cell lymphocytosis
45. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
46. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice
47. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia
48. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
49. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases
50. OP0021 PREDICTING SEVERE INFECTION IN REPEAT CYCLES OF RITUXIMAB AND EFFECTS OF HYPOGAMMAGLOBULINAEMIA FOR THE TREATMENT OF RHEUMATIC AND MUSCULOSKELETAL DISEASES
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.